in the absence of a submission from the holder of the marketing authorisation:
ceftolozane/tazobactam (Zerbaxa®) is not recommended for use within NHSScotland.
Indication under review: In adults for the treatment of hospital acquired pneumonia, including ventilator-associated pneumonia.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice357KB (PDF)
- Medicine name:
- ceftolozane/tazobactam (Zerbaxa)
- SMC ID:
In adults for the treatment of hospital acquired pneumonia, including ventilator-associated pneumonia.
- Pharmaceutical company
- Merck Sharp & Dohme Ltd
- BNF chapter
- Respiratory system
- Submission type
- Non submission
- Not recommended
- Date advice published:
- 09 December 2019